体外膜氧合用于难治性哮喘急性发作伴呼吸衰竭
该回顾性队列研究基于2010至2020年美国全国行政数据集(覆盖25%住院病例),纳入13,714例接受短效支气管舒张剂、全身糖皮质激素和有创机械通气的哮喘急性发作伴呼吸衰竭(AERF)患者,其中127例接受ECMO。
要点
- 难治性AERF患者接受ECMO与住院死亡率降低相关,校正后OR 0.33-0.48。
- ECMO与住院费用增加相关,但未缩短ICU住院时间、总住院时间或有创通气时间。
- 结果提示ECMO可作为难治性AERF的挽救治疗,尚需确证性临床试验。
核心结论
- ECMO与难治性AERF患者住院死亡率降低相关,但住院费用增加。
研究设计与样本
- 回顾性、流行病学、观察性队列研究,使用2010至2020年美国全国行政数据集,覆盖25%美国住院病例。
- 纳入因哮喘急性发作入住具备ECMO能力医院并接受短效支气管舒张剂、全身糖皮质激素和有创通气的患者,排除年龄<18岁、无ICU停留、非哮喘慢性肺病、COVID-19或多次入院者。
- 共分析13,714例AERF患者,其中ECMO组127例,无ECMO组13,587例。
主要发现
- 敏感性分析显示ECMO相关死亡风险降低的OR范围为0.34至0.61。
临床怎么用
- 对于难治性AERF患者,ECMO可考虑作为挽救治疗,但需权衡费用增加及未缩短住院时间。
- ECMO的获益尚需确证性临床试验验证,当前证据来自观察性研究。
局限性
- 回顾性观察性研究设计,可能存在未测量混杂。
- 使用行政数据集,临床细节和ECMO指征等信息可能有限。
- ECMO组样本量较小(127例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Asthma exacerbations with respiratory failure (AERF) are associated with hospital mortality of 7% to 15%. Extracorporeal membrane oxygenation (ECMO) has been used as a salvage therapy for refractory AERF, but controlled studies showing its association with mortality have not been performed. RESEARCH QUESTION: Is treatment with ECMO associated with lower mortality in refractory AERF compared with standard care? STUDY DESIGN AND METHODS: This is a retrospective, epidemiologic, observational cohort study using a national, administrative data set from 2010 to 2020 that includes 25% of US hospitalizations. People were included if they were admitted to an ECMO-capable hospital with an asthma exacerbation, and were treated with short-acting bronchodilators, systemic corticosteroids, and invasive ventilation. People were excluded for age < 18 years, no ICU stay, nonasthma chronic lung disease, COVID-19, or multiple admissions. The main exposure was ECMO vs No ECMO. The primary outcome was hospital mortality. Key secondary outcomes were ICU length of stay (LOS), hospital LOS, time receiving invasive ventilation, and total hospital costs. RESULTS: The study analyzed 13,714 patients with AERF, including 127 with ECMO and 13,587 with No ECMO. ECMO was associated with reduced mortality in the covariate-adjusted (OR, 0.33; 95% CI, 0.17-0.64; P = .001), propensity score-adjusted (OR, 0.36; 95% CI, 0.16-0.81; P = .01), and propensity score-matched models (OR, 0.48; 95% CI, 0.24-0.98; P = .04) vs No ECMO. Sensitivity analyses showed that mortality reduction related to ECMO ranged from OR 0.34 to 0.61. ECMO was also associated with increased hospital costs in all three models (P < .0001 for all) vs No ECMO, but not with decreased ICU LOS, hospital LOS, or time receiving invasive ventilation. INTERPRETATION: ECMO was associated with lower mortality and higher hospital costs, suggesting that it may be an important salvage therapy for refractory AERF following confirmatory clinical trials.
引用
- Zakrajsek, Min, Ho, et al. Extracorporeal Membrane Oxygenation for Refractory Asthma Exacerbations With Respiratory Failure. Chest. 2022. PMID: 36191634. doi:10.1016/j.chest.2022.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。